Substituted Aminobutyric Derivatives as Neprilysin Inhibitors
AssigneeNovartis AG
InventorsGary Mark Coppola, Yuki Iwaki, Rajeshri Ganesh Karki, Toshio Kawanami, Gary Michael Ksander, Muneto Mogi, Robert Sun
Life of this patent
Estimating the term…
Abstract
The present invention provides a compound of formula I′; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Claims19
A compound of the formula (I′):
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is C1-7alkyl;
- for each occurrence, R2 is independently C1-7alkyl, NO2, CN, halo, C3-7cycloalkyl, hydroxy, C1-7alkoxy, halo-C1-7alkyl, NRbRc, C6-10aryl, heteroaryl or heterocyclyl;
- wherein Rb and Rc for each occurrence, are independently H or C1-7alkyl;
- R3 is A1C(O)X1 or A2-R4;
- R4 is C6-10aryl or a heteroaryl, which can be monocyclic or bicyclic and which can be optionally substituted with one or more substituents independently selected from hydroxy, hydroxy-C1-7alkyl, NRbRc, nitro, C1-7alkoxy, halo, C1-7alkyl, halo-C1-7alkyl, C2-7alkenyl, C6-10aryl, heteroaryl, —C(O)C1-7alkyl, —NHS(O)2-C1-7alkyl, —SO2C1-7alkyl and benzyl;
- R5 is H, halo, hydroxy, C1-7alkoxy, halo, C1-7alkyl or halo-C1-7alkyl;
- and
- X and X1 are independently OH, —O—C1-7alkyl, —NRbRc, —NHS(O)2—C1-7alkyl, —NHS(O)2-benzyl or —O—C6-10aryl;
- wherein alkyl is optionally substituted with one or more substituents independently selected from the group consisting of aryl, heteroaryl, heterocyclyl, —C(O)NH2, —C(O)NH—C1-6alkyl, and —C(O)N(C1-6alkyl)2;
- A1 is a bond or a linear C1-4alkylene substituted with one or more substituents independently selected from the group consisting of halo, O-acetate, C1-7 alkyl and C3-7cycloalkyl;
- in which two geminal alkyl can optionally combine to form a C3-7cycloalkyl;
- or
- A1 is a linear or branched C2-6alkenylene;
- or
- A1 is a linear C1-4 alkylene wherein one or more carbon atom(s) is/are replaced with an heteroatom selected from O, NRa;
- and A1 is optionally substituted with one or more substituents independently selected from the group consisting of halo and C1-7alkyl;
- in which Ra for each occurrence, is independently H, C1-7alkyl or CH2C(O)OH;
- or
- A1 is a C3-7cycloalkyl, a heterocyclyl, a phenyl or a heteroaryl in which phenyl and heteroaryl are optionally substituted with one or more substituents independently selected from the group consisting of C1-7alkyl, C3-7cycloalkyl, halo-C1-7alkyl, hydroxy, C1-7alkoxy, halo, NRbRc, OCH2CO2H, and OCH2C(O)NH2;
- or
- A1 is —C1-4alkylene-C6-10-aryl-, —C1-4alkylene-heteroaryl- or —C1-4alkylene-heterocyclyl-, wherein
- A1 may be in either direction;
- and
- A2 is a bond or a linear or branched C1-7alkylene which is optionally substituted with one or more substituents independently selected from the group consisting of halo, C1-7alkoxy, hydroxy, O-Acetate and C3-7cycloalkyl;
- n is 0, 1, 2, 3, 4 or 5;
- wherein each heteroaryl is a monocyclic or bicyclic aromatic ring comprising 5-10 ring atoms selected from carbon atoms and 1 to 5 heteroatoms, and
- each heterocyclyl is a monocyclic saturated or partially saturated but non-aromatic moiety comprising 4-7 ring atoms selected from carbon atoms and 1-5 heteroatoms, wherein each heteroatom of a heteroaryl or a heterocyclyl is independently selected from O, N and S.
A pharmaceutical composition comprising a compound according to any one of claims 1, 4, 9, 21 or 22 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.
A method of treating a disorder or a disease associated with neutral endopeptidase EC. 3.4.24.11. activity in a subject in need thereof, comprising:
- administering to the subject a therapeutically effective amount of the compound according to any one of claims 1, 4, 9, 21 or 22 or a pharmaceutically acceptable salt thereof.
17-19. (canceled)
Dependencies are inferred from the claim text.